Bupropion: Clinical Trials

51 trials of Bupropion, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed, 6 terminated, 4 recruiting, 2 active not recruiting. 51 Phase 3, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 351Completed 35, Terminated 6, Recruiting 4, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1
Phase 215Completed 12, Terminated 2, Unknown 1

Follow Bupropion: new trials by email Literature Review of Bupropion trials Research Report on Bupropion

Trials (filtered) newest first · largest first

All 51 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk
Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk
Phase 3Not yet recruitingUppsala University2502026-10-302026-09-08
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo - Smoking Cessation
Phase 3RecruitingAxsome Therapeutics, Inc.7052026-08-272026-11-06
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder
Phase 3TerminatedDr. Inge Winter12025-04-272026-11-05
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Escitalopram, Sertraline, Venlafaxine - Bipolar Depression
Phase 3RecruitingDr. Inge Winter4182025-02-112025-09-26
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB - Methamphetamine-dependence, Methamphetamine Abuse
Phase 3Active not recruitingNational Institute on Drug Abuse (NIDA)3602024-07-012026-07-13
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Inavolisib, Fulvestrant, Alpelisib - Breast Cancer
Phase 3RecruitingHoffmann-La Roche4202023-06-072026-10-26
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
Bupropion - Smoking Cessation
Phase 3RecruitingUniversity of Kansas Medical Center5002023-02-282026-02-23
Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)
Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight
Phase 2 / Phase 3CompletedYale University242022-06-102026-08-26
The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
Bupropion, Zonisamide, Placebo bupropion - Smoking Cessation
Phase 3CompletedRose Research Center, LLC1802021-12-142026-02-06
Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya
Bupropion, Positively smoke free, Brief advice to quit smoking - HIV, Smoking Cessation
Phase 3CompletedUniversity of Maryland, Baltimore3002020-08-012025-02-05
Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
Zonisamide, Bupropion, Halo G6 e-cigarette - Smoking Cessation
Phase 3CompletedRose Research Center, LLC262020-05-272022-04-13
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant
Phase 3WithdrawnJanssen-Cilag International NV2019-12-012025-04-27
Open-Label Safety Study of AXS-05 in Subjects With Depression
AXS-05 (dextromethorphan and bupropion) oral tablets - Major Depressive Disorder, Treatment Resistant Depression
Phase 3CompletedAxsome Therapeutics, Inc.8762019-07-082022-10-12
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Phase 3Active not recruitingUniversity of Rochester NCORP Research Base4222019-06-272026-09-30
Individualizing Pharmacotherapy for African American Smokers
Nicotine patch, Varenicline Tartrate, Bupropion - Smoking Cessation
Phase 3CompletedUniversity of Kansas Medical Center3922019-05-012023-04-03
Individualized Obesity Pharmacotherapy
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion - Obesity
Phase 3CompletedMayo Clinic1932017-12-112023-07-18
Addressing Dementia Via Agitation-Centered Evaluation
AXS-05, Bupropion, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Phase 2 / Phase 3CompletedAxsome Therapeutics, Inc.3662017-07-132023-09-13
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
AXS-05, Bupropion - Treatment Resistant Major Depressive Disorder
Phase 3CompletedAxsome Therapeutics, Inc.3122016-03-012021-03-24
Web-based Smoking Cessation Program for Tribal College Students
Internet-All Nations Breath of Life (I-ANBL), Honoring the Gift of Heart Health, Nicotine gum, Patch, or Lozenge or Zyban® or Chantix® - Smoking Cessation
Phase 3CompletedWon Choi, PhD, MPH2512015-05-012021-12-07
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Bupropion, Bupropion Matching Placebo, Escitalopram - Depressive Disorder, Major
Phase 3CompletedGlaxoSmithKline5342015-02-102020-02-25

Showing 20 of 51. Sign in to see all of them.

Conditions studied

Smoking Cessation (19)  ·  Tobacco Use Disorder (11)  ·  Smoking (9)  ·  Depression (7)  ·  Depressive Disorder, Major (6)  ·  Obesity (4)  ·  Cigarette Smoking (3)  ·  Depressive Disorder, Treatment-Resistant (3)  ·  Bipolar Disorder (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (2)  ·  Overweight (2)  ·  Schizophrenia (2)  ·  Vaping (2)  ·  Acute Coronary Syndrome (1)

Sponsors

Axsome Therapeutics, Inc. (4)  ·  Duke University (4)  ·  National Institute on Drug Abuse (NIDA) (4)  ·  University of Kansas Medical Center (3)  ·  Dr. Inge Winter (2)  ·  M.D. Anderson Cancer Center (2)  ·  Mayo Clinic (2)  ·  New York State Psychiatric Institute (2)  ·  Rose Research Center, LLC (2)  ·  University of California, San Francisco (2)  ·  University of Minnesota (2)  ·  Yale University (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Altschuler, Eric, M.D. (1)  ·  AstraZeneca (1)

Countries

United States (42)  ·  Canada (5)  ·  Germany (4)  ·  Australia (3)  ·  Belgium (2)  ·  China (2)  ·  France (2)  ·  Italy (2)  ·  Poland (2)  ·  South Africa (2)  ·  Spain (2)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Austria (1)

Top investigators

Jed E Rose, Ph.D. (3)  ·  Marc E Mooney, Ph.D. (2)  ·  A. Daigneault, Dr. (1)  ·  A. Ravindran, Dr. (1)  ·  A. Schaffer, Dr. (1)  ·  A.V. Mysore, Dr. (1)  ·  Andres J Acosta (1)  ·  B. Frey, Dr. (1)  ·  Beth L Murphy, MD, PhD (1)  ·  David Kalman, PhD (1)  ·  Dorothy Hatsukami, PhD (1)  ·  Edward F. Ellerbeck, MD, MPH (1)  ·  Ellen R. Gritz, PhD (1)  ·  Eric A Dedert, PhD (1)

Results publications

PMID 37230961, PMID 37142273, PMID 34611902, PMID 41401709, PMID 16102908, PMID 16801293, PMID 17624979, PMID 18065851, PMID 18236294, PMID 18397444, PMID 18420774, PMID 18447101, PMID 18544464, PMID 19023824, PMID 19349629, PMID 19358791, PMID 19392908, PMID 19730273, PMID 19730274, PMID 19778993, PMID 19901150, PMID 21233256, PMID 22097928, PMID 22770436, PMID 23128154, PMID 23497790, PMID 23536105, PMID 23640009, PMID 23656848, PMID 23672772, PMID 24067192, PMID 24108148, PMID 24175721, PMID 24329972, PMID 24399554, PMID 24440324, PMID 24816198, PMID 24934962, PMID 25326910, PMID 26474010, PMID 27213949, PMID 29679432, PMID 30664539, PMID 33687070, PMID 33759389, PMID 36387983, PMID 37335995, PMID 37338906, PMID 37530824, PMID 39868569

NIH funding

K01DA019446 (2), P50DA027840 (2), 2018 (1), 2023 (1), K23DK071646 (1), R01CA101963 (1), R01CA138417 (1), R01CA174481 (1), R01CA214647 (1), R01DA002538 (1), R01DA011444 (1), R01DA013490 (1), R01DA017073 (1), R01DA017370 (1), R01DA024709 (1)